Renaissance Technologies LLC Increases Position in MaxCyte, Inc. (NASDAQ:MXCT)

Renaissance Technologies LLC lifted its stake in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 29.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 210,914 shares of the company’s stock after acquiring an additional 48,314 shares during the quarter. Renaissance Technologies LLC owned 0.20% of MaxCyte worth $827,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of MXCT. Price T Rowe Associates Inc. MD boosted its stake in shares of MaxCyte by 20.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company’s stock worth $106,000 after buying an additional 4,320 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of MaxCyte by 22.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company’s stock valued at $128,000 after purchasing an additional 5,927 shares during the period. PNC Financial Services Group Inc. purchased a new stake in shares of MaxCyte during the fourth quarter valued at approximately $29,000. Russell Investments Group Ltd. bought a new stake in shares of MaxCyte in the first quarter worth $28,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of MaxCyte by 65.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 19,884 shares of the company’s stock worth $83,000 after buying an additional 7,898 shares during the last quarter. Hedge funds and other institutional investors own 68.81% of the company’s stock.

MaxCyte Stock Performance

Shares of MXCT opened at $3.78 on Tuesday. The company has a market cap of $396.23 million, a price-to-earnings ratio of -10.80 and a beta of 1.39. The firm has a fifty day moving average of $4.11 and a 200-day moving average of $4.24. MaxCyte, Inc. has a 1 year low of $2.77 and a 1 year high of $5.55.

MaxCyte (NASDAQ:MXCT) last issued its earnings results on Tuesday, August 6th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.05. The company had revenue of $10.43 million for the quarter, compared to the consensus estimate of $8.20 million. MaxCyte had a negative return on equity of 15.52% and a negative net margin of 77.97%. During the same quarter in the prior year, the company earned ($0.10) EPS. Analysts predict that MaxCyte, Inc. will post -0.44 EPS for the current year.

Insider Activity

In other MaxCyte news, Director Stanley C. Erck sold 29,767 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.97, for a total transaction of $118,174.99. Following the completion of the transaction, the director now directly owns 269,118 shares in the company, valued at $1,068,398.46. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other MaxCyte news, Director Stanley C. Erck sold 29,767 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.97, for a total transaction of $118,174.99. Following the transaction, the director now owns 269,118 shares in the company, valued at approximately $1,068,398.46. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Thomas M. Ross sold 15,476 shares of MaxCyte stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $4.54, for a total value of $70,261.04. Following the transaction, the executive vice president now owns 25,000 shares in the company, valued at $113,500. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 75,850 shares of company stock valued at $307,148. 3.00% of the stock is owned by company insiders.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.